DDInter117 DDInter899
Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Argatroban {u} (Compound) binds {v} (Gene) CYP3A4
Argatroban {u} (Compound) is included by {v} (Pharmacologic Class) Thrombin Inhibitors
Argatroban {u} (Compound) causes {v} (Side Effect) Haemorrhage
Argatroban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Argatroban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Choline salicylate
Argatroban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Argatroban {u} may lead to a major life threatening interaction when taken with {v} Streptokinase
Argatroban {u} may lead to a major life threatening interaction when taken with {v} Danaparoid
Argatroban (Compound) binds CYP3A4 (Gene)
Argatroban (Compound) is included by Thrombin Inhibitors (Pharmacologic Class)
Argatroban (Compound) causes Haemorrhage (Side Effect)
Argatroban may cause a minor interaction that can limit clinical effects when taken with Clove
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Argatroban may lead to a major life threatening interaction when taken with Streptokinase
Argatroban may lead to a major life threatening interaction when taken with Danaparoid